Broker sees 'strong asymmetric upside risk' for ResMed shares

Goldman Sachs is recommending investors snap up this beaten down share.

| More on:
A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ResMed Inc (ASX: RMD) shares have really taken a beating in recent months.

Concerns over the emergence of obesity drugs have weighed heavily on sentiment.

But has this all been a huge overreaction? The team at Goldman Sachs appears to believe that this is the case and is urging investors to snap up the company's shares while they're dirt cheap.

What is Goldman Sachs saying?

Goldman notes that semaglutide (branded as Ozempic, Rybelsus or Wegovy) and tirzepatide (branded as Mounjaro) belong to a class called GLP-1/GIP-receptor agonists.

While these drugs were initially targeting type 2 diabetes, they have consistently demonstrated clear efficacy in weight management and cardiovascular indications.

Given that obstructive sleep apnoea (OSA) is "an indication that is correlated with weight and cardiovascular comorbidities," the broker acknowledges that there are concerns about the impact these drugs could have on demand for ResMed's industry-leading technology.

However, its research shows that the two treatments can grow strongly together over the long term. Particularly given that "OSA remains under-penetrated, with global estimates suggesting <20% and many countries well-below this level."

The base case for ResMed

Goldman has outlined its base case for ResMed in a world with obesity drugs. It explains:

Our base scenario adopts our base case obesity forecasts from above (i.e. -7% reduction in obese or overweight with comorbidity population by 2030E). It then assumes the following patient retention on CPAP (mild 55%; moderate 70%; severe 80%). In this scenario we could see only a modest benefit of AHI [Apnea-Hyponea Index] in GPI-2 over GPI-1, which could result in a lower level of patients.

Overall, we expect continued adoption/success of the GLP-1/GIP class to reduce the OSA population addressable by CPAP, but the impact to RMD/FPH is mitigated by: i) long-term market share gains from competitors; and ii) continued improvements in OSA diagnosis rates (potentially catalysed by the GLP-1/GIP class itself).

ResMed shares have 'strong asymmetric upside'

Goldman highlights that its analysts "see strong asymmetric upside risk from current levels."

According to the note, the broker has reiterated its buy rating on ResMed's shares with a reduced price target of $33. This implies a potential upside of almost 53% for investors over the next 12 months.

Motley Fool contributor James Mickleboro has positions in ResMed. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Private health insurance diagram.
Healthcare Shares

What's Macquarie's price target for NIB shares?

Is the broker positive or negative on NIB's shares?

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Guess which ASX healthcare stock is rocketing 42% on Pro Medicus investment

Let's see what is going on today with this small cap.

Read more »

Six smiling health workers pose for a selfie.
Earnings Results

ResMed share price hits record high on strong FY25 results

This healthcare giant is ending the week positively thanks to its strong results.

Read more »

Two doctors smile as they sit together at a desk looking at a patient's x-ray.
Healthcare Shares

Why Macquarie rates this ASX All Ords medical imaging stock a buy

The broker maintains its outperform rating on the stock.

Read more »

A man in a hospital bed on a drip gives a thumbs up sign.
Healthcare Shares

Macquarie predicts 86% upside for this ASX 200 healthcare stock

Shares could almost double over the next 12 months, according to the broker.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

Ozempic maker Novo Nordisk plunges 22%. What could this mean for Resmed shares?

Novo Nordisk just lost $100 billion in market value.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 11% today

Let's see why investors are bidding this stock higher on Wednesday.

Read more »

stockmarket graphic in background with man looking at stockmarket on phone
Healthcare Shares

CSL shares are a buy – UBS

This expert is optimistic on what the business can achieve despite headwinds.

Read more »